Anavex Life Sciences Corp (AVXL)

[TrueTrades]

Little Orphan Anavex and the Big Bad Market

"We doubt that there’s a company more hated than Anavex Life Sciences Corp (NASDAQ:AVXL) trading on the NASDAQ. Countless negative articles, tweets, and irrational pessimism has plagued the company since the beginning. Granted the company did start as a reverse merger and did not go the traditional IPO route, but the company has been committed to Alzheimer’s research and the science behind the company is real. It seems more are rooting for the company to fail than succeed and we find this astonishing."
http://www.insiderfinancial.com/anavex-life-sciences-corp-nasdaqavxl-defies-the-bears/115200/

The market loves it's money. It likes it's big, fat IPOs that provide instant returns for dumping overpriced securities on the sheeple. It does not like retail holding 20% of the float with an iron fist....no no no!

A rundown of our Board Of Directors provides the scenario:

Anavex BOD:

Christopher U. Missling M.S., Ph.D., M.B.A. - Executive Director

Dr. Christopher U. Missling, also known as the Chris, MS, Ph.D., MBA. has been the Chief Executive Officer and President of Anavex Life Sciences Corp. since July 05, 2013 and served as its Chief Financial Officer, Secretary and Treasurer since July 05, 2013. Dr. Missling serves as the Chief Financial Officer of SEE ALGAE Technology GmbH. Dr. Missling is a Partner of New York based investment bank Brimberg & Co and has over 15 years of finance experience. He is an Investment Banker at Deutsche Bank, serving companies across various industries. Dr. Missling served as Senior Vice President of Finance, Treasurer and Secretary of Asahi Kasei Pharma America Corporation (Previously known as Artisan Pharma, Inc.) Dr. Missling has extensive financial management, operational and strategic experience in the biotechnology and pharmaceutical industries. Dr. Missling served as the Chief Financial Officer of ImmunoGen Inc., from October 25, 2004 to January 2005 and also served as its Vice President of Finance and Treasurer. He also served as Chief Financial Officer, Senior Vice President of Finance, Treasurer and Secretary of Curis, Inc. from August 2002 to November 2003 and Senior Vice President of Strategic Analysis and Planning from November 2003. Dr. Missling served as Chief Financial Officer of Axaron Bioscience AG from November 2001 to August 2002. From October 2001 to January 2002, Dr. Missling served as Head of Financial Planning of Aventis SA, with responsibility for financial modeling and determining investment valuations. From July 1997 to December 1999, he served as Head of Financial Planning at Hoechst AG. Dr. Missling was with Deutsche Bank in corporate finance and investment banking serving pharmaceutical, biotech, and diagnostic companies. He served as an Analyst in the pharmaceutical /healthcare investment banking group of Deutsche Morgan Grenfell. He serves as a Member of Scientific Advisory Board at Anavex Life Sciences Corp. Dr. Missling serves as the Chairman at Anavex Life Sciences Corp. and has been its Director since July 5, 2013. Dr. Missling received his MBA from the Kellogg Graduate School of Management at WHU and Northwestern University, with a focus on partnership valuations in the Biotechnology and Pharmaceutical industries, and his Ph.D., in Chemistry, summa cum laude, and MSc from Ludwig-Maximilians-University in Munich.

*The Chris? We call him ze Terminator!

Athanasios "Tom" Skarpelos - Founding Director

Mr. Athanasios Skarpelos, also known as Tom, founded Anavex Life Sciences. Mr. Skarpelos served as a Consultant to Anavex Life Sciences since August 2, 2010. His experience has led to relationships with researchers at academic institutes in Europe and North America. Mr. Skarpelos is a self-employed investor with 17 years of experience and worked with private and public companies. For 10 years, he focused on biotechnology companies involved in drug discovery and drug development projects. Mr. Skarpelos has been a Director of Anavex Life Sciences Corp. since January 9, 2013.

*Not much info is available about Mr Skarpelos. He founded the company and formed it with Harvey Lalach in 2006. Now Harvey Lalach is well known in Canadian penny stock land. He was involved with Assure Energy, Globalenetcare, First Cypress Technologies and InstaPay Systems. He is where the penny stock scam implication comes from. He also sits on the BOD of La Jolla LJPC where George Tidmarsh, a former Anavex Director, is CEO. Anavex and Mr lalach parted ways in 2012. It looks like he may still hold ~140KK:
http://www.sec.gov/cgi-bin/browse-edgar?CIK=0001360545&action=getcompany

I believe the meeting of Uncle Tom Skarpelos and Dr Vamvakides is what initiated the pipeline and company and it is the Greek connection. Associations in Canada will always be with us and will be used to discredit the company. Nothing new for the Canadian connection!

Elliot Favus M.D. - Independent Director

Dr. Elliot Favus, M.D is the Founder of Favus Institutional Research, LLC and serves as its Chief Executive Officer. Dr. Favus serves as a Business Advisor of Science House Capital. He has an expertise in Healthcare Equity Research. He has been Healthcare Equity Research Analyst at Wall Street since 2006, at Lazard Capital Markets and Och-Ziff Capital Management Group. Prior to working on Wall Street, Dr. Favus was an Instructor in Medicine at Mount Sinai School of Medicine in New York. Since 2004, he is board-certified in Internal Medicine. He has been an Independent Director of Anavex Life Sciences Corp. since May 07, 2014. Dr. Favus has 10 years of basic science laboratory experience, working on human genetics projects at Harvard Medical School, The University of Chicago, and the University of Pittsburgh. Dr. Favus completed the NYU-Bellevue Hospital Internal Medicine Residency Program in 2004, and earned an M.D. from the University of Chicago Pritzker School of Medicine in 2001, and a B.A. from The University of Michigan in 1996.

*Dr Favus runs a well respected Institutional Research Provider (IRP) firm, Favus Institutional Research. His reports leaked by squakboxes like AF have had much impact on biotech stocks. His board membership is a huge plus for Anavex and a sign of validity.

Bernd Metzner Ph.D. - Independent Director

Dr. Bernd Metzner, PhD, has been the Chief Financial Officer of Ströer SE (formerly known as Ströer Media AG) since June 16, 2014 and has been its Member of Management Board since June 2014. Dr. Metzner serves as Chief Financial Officer of the Doehler Group. Dr. Metzner served as a Member of the Executive Board at Döhler GmbH. Dr. Metzner served as the Chief Administrator and member of the Board of Management at Bayer Schering Pharma AG. Dr. Metzner held worldwide financial responsibility for the Bayer Pharma Group. In his almost 10-years with Bayer AG, Dr. Metzner held several senior international management positions in the corporate finance organization of Bayer AG, including Chief Financial Officer of Bayer S.p.A. Italy and heading the coordination of the successful spin-off of Lanxess. Dr. Metzner started his career at the law firm Flick Gocke Schaumburg. Dr. Metzner served as Head of Finance - Bayer Italy. Mr. Metzner served as Member of the Board of Management of Bayer Schering Pharma AG since October 1, 2008. He has been an Independent Director of Anavex Life Sciences Corp. since May 7, 2014. He studied business administration at the University of Siegen and, after obtaining his doctorate, he became a chartered accountant.

*Now check Dr Metzner's board affiliations:
http://www.bloomberg.com/research/stocks/people/relationship.asp?personId=47097392

He is now vested with AVXL stock otions. Missling and Metzner...the German connection, and why I believe our Suitor has always been Bayer AG.

Steffen Thomas Ph.D. - Independent Director

Dr. Steffen Thomas, Ph.D. has been a Director of Anavex Life Sciences Corp. since June 2015. Dr. Thomas has over 15 years of experience as a European patent attorney and is currently practicing at Epping Hermann Fischer, a major intellectual property law firm in Europe. Previously, he worked for Japan-based Takeda Pharmaceutical Company, the largest pharmaceutical company in Asia and a top firm worldwide, as an in-house patent attorney. Prior to that, he worked for Nycomed Pharma, acquired by Takeda in 2011 for approximately USD $10 billion. Dr. Thomas’ legal practice covers drafting of patent applications, prosecuting patent applications before national and international patent offices, defending and challenging patents in opposition, appeal, and nullity proceedings, enforcing patents before the infringement courts, and preparing opinions on patentability and infringement in the technical field of chemistry. Dr. Thomas has particular expertise in small molecule pharmaceuticals. He holds MS and PhD degrees in Chemistry from the University of Munich.

*Our German patent litigation specialist. The IP is in good hands.

It is easy to see why Wall St is afraid of the little redhead...she just might be for real!

"You love money and power and capitalism? You know they’re never going to love you back…" -Annie
§